2a) decreased substantially with time, from 60% in 2000 to 43% in 2010. Smoking prevalence was lower

Selleck DAPT in participants in the care of private physicians. Observed patterns were very different among the HIV transmission group categories (Fig. 2b). In the year 2000, the prevalence of smoking at the Zurich SHCS centre (64%) was higher than at all other centres (61%), or among participants in the care of private physicians (55%), and it decreased in all care settings, with a more pronounced decrease at the Zurich centre (–22.5%) than in other centres (–16.5%) or in private practices (–14.5%) (Fig. 2a). Smoking prevalence among HIV-positive persons has always been higher than in the general population in Switzerland (Fig. 2c) [30, 31]. Some of these differences may be attributable to differences in age distributions, with older persons, who are less likely to smoke, being underrepresented in the SHCS. For example, in 2009 only 14% of SHCS participants were aged 55 years or above, compared with 40% in the general Swiss population [31]. www.selleckchem.com/products/CAL-101.html Smoking cessation was observed 2019 times during 29 541 person-years for 5805 SHCS participants; and smoking relapses occurred 1390 times during 12 055 person-years

for 1953 participants from 2000 to 2010. The resulting incidences were 6.8 [95% confidence interval (CI) 6.5–7.1] per 100 patient-years for smoking cessation, and 11.5 (95% CI 10.9–12.2) per 100 patient-years for relapses. Incidences varied considerably

across settings and over time: values for smoking cessation in 2004, 2007 (just prior to the intervention) and 2010 (after 3 years of the intervention) were 5.0 (95% CI 3.6–6.9), 6.1 (95% CI 4.6–8.1) and 10.8 (95% CI 7.9–14.6) per 100 patient-years at the Zurich centre, 5.2 (95% CI 4.2–6.6), 4.4 (95% CI 3.5–5.5) and 6.2 (95% CI 4.7–8.2) at other centres, and 5.4 (95% CI 4.2–7.0), 7.5 (95% CI 6.1–9.2) and 7.6 (95% CI 5.7–10.1) for private practices, respectively. Values for cessation relapses in 2004, 2007 and 2010 were 11.2 (95% CI 7.7–16.2), 8.7 (95% CI 6.1–12.4) and 2.9 (95% CI 1.3–6.5) per 100 patient-years at the Zurich centre, whereas incidences Astemizole were 10.5 (95% CI 7.8–14.2), 10.9 (95% CI 8.4–14.1) and 9.2 (95% CI 6.6–12.9) for other centres, and 10.8 (95% CI 8.1–14.4), 10.6 (95% CI 8.4–13.5) and 7.3 (95% CI 4.7–11.4) for private practices, respectively. Results from marginal logistic regression models are displayed in Table 3 for smoking cessation and Table 4 for relapses. Although the models for cessation events and relapse events include partly different person groups, effect estimates for the different covariables are very symmetrical across all models (i.e. factors which are negatively associated with cessation events were positively associated with relapse events). Therefore, only the models for cessation events are described in more detail.